Skip to content

LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

LUMIGAN® 0.01% was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.1,2

INDICATION

LUMIGAN® (bimatoprost ophthalmic solution) 0.01% is used for the reduction of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

LUMIGAN® (bimatoprost ophthalmic solution) 0.01% can cause increased brown coloring of the iris, which may be permanent. LUMIGAN® 0.01% can cause darkening of the eyelid skin and eyelashes, which may be reversible after treatment is stopped. The long-term effects of increased dark coloring are not known.

LUMIGAN® 0.01% may slowly increase the growth and thickness of eyelashes, which are usually reversible after treatment is stopped.

Prostaglandin analogs, including bimatoprost, have been reported to cause inflammation inside the eye. Also, treatment with LUMIGAN® 0.01% may make existing inflammation worse.

Macular edema (swelling of the macula), including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. LUMIGAN® 0.01% should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Avoid allowing the tip of the dispensing bottle to touch the eye, anything around the eye, fingers, or any other surface to avoid contamination by common bacteria known to cause eye infections. Using contaminated solutions can cause serious damage to the eye and loss of vision.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing the use of LUMIGAN® 0.01%.

If you wear contact lenses, remove them before using LUMIGAN® 0.01%. Then wait 15 minutes after using LUMIGAN® 0.01% before you put your contacts back into your eyes.

The most common side effect is eye redness. Other side effects include growth of eyelashes and itchy eyes.

Please See Full LUMIGAN® Product Information (PDF) 
LUMIGAN® Web site 


APC60IO15



  1. 2010 LUMIGAN® (bimatoprost ophthalmic solution) 0.01% FDA Approval Letter
  2. 2014 LUMIGAN® (bimatoprost ophthalmic solution) 0.01% Prescribing Information